A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of JNJ-63623872 on the QT/QTc interval at
supratherapeutic exposure in healthy participants (Panel 2).
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination